Elgia Therapeutics is a newly established venture-backed biotech company pursuing novel approaches for the treatment of chronic inflammatory and fibrotic diseases. Elgia was founded by UCSD and UCSF scientists Alan Saltiel, Ariel Feldstein, Michael Karin, Michelle Arkin, and Adam Renslo, who are world leaders in the biology of innate immunity, inflammation and wound healing, as well as in the biochemistry and pharmacology of key enzymes that control inflammation and cell demise. Leveraging the expertise of our founders, Elgia will use high throughput chemical screening coupled with structure-based design to discover and develop novel inhibitors of these targets.
